| US 7,521,460 B2 | ||
| Thienopyridone derivatives as kinase inhibitors | ||
| Daniel Christopher Brookings, Reading (United Kingdom); Jeremy Martin Davis, Wokingham (United Kingdom); and Barry John Langham, Reading (United Kingdom) | ||
| Assigned to UCB Pharma S.A., Brussels (Belgium) | ||
| Appl. No. 10/561,052 PCT Filed Jun. 18, 2004, PCT No. PCT/GB2004/002621 § 371(c)(1), (2), (4) Date Oct. 10, 2006, PCT Pub. No. WO2004/113347, PCT Pub. Date Dec. 29, 2004. |
||
| Claims priority of application No. 0314492.0 (GB), filed on Jun. 20, 2003; and application No. 0329485.7 (GB), filed on Dec. 19, 2003. | ||
| Prior Publication US 2007/0099894 A1, May 03, 2007 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A01N 43/42 (2006.01); A61K 31/44 (2006.01); C07D 513/02 (2006.01); C07D 515/02 (2006.01) | ||
| U.S. Cl. 514—301 [546/114] | 11 Claims |
1. A compound of formula (1):
 Y is a linking group —C(O)— or —S(O)2—;
n is zero or the integer 1;
m is the integer 1, 2, 3 or 4;
p is the integer 1, 2, 3 or 4;
Rd is —OH, -(Alk2)OH, —OR1, -(Alk2)OR1, —NR2R3, -(Alk2)NR2R3 or a straight or branched C1-6 alkyl group;
Alk2 is a straight or branched C1-4 alkylene chain;
R1 is a straight or branched C1-6 alkyl group;
R2 and R3, which may be the same or different, are each independently a hydrogen atom or a straight or branched C1-6 alkyl group;
Alk1 is a straight or branched C1-4 alkylene chain;
Cy1 is an optionally substituted cycloaliphatic, aromatic or heteroaromatic group; and
Ar is an optionally substituted aromatic or heteroaromatic group; or a salt or N-oxide thereof.
|